First attempt at Gene Therapy for Parkinson's disease in the United States

since the rise of biotechnology, scientists have had high hopes for the use of gene therapyIn the first attempt at gene therapy for Parkinson's disease, U.Sresearchers have made significant progress in the study's ability to control the body significantlyResearchers at Cornell University's Weill School of Medicine conducted a pilot study of the "Trojan Horse" therapy in New York11menand afemale, the Times of London reported on June 22Previous studies have shown that people with Parkinson's disease experience excessive activity in the hypothalamus nucleus of the brain, blocking signals back into the nervous system and thus preventing the body frommovementcontrolGene therapy focuses on the gene encoded as glutamate aplysase (GAD), an enzyme that promotes the generation of central nerve transmitters, which helps control chemical signals between nerve cellsThe researchers inserted the GAD gene into a virus that was incapacitated to cause disease, sending the GAD gene to the hypothalamus, a target region of the brain, and promoting the production of enzymes in that region, which reduced the excited nerve signals and increased inhibition signals and balanced brain activityThe researchers implanted the GAD gene on one side of the brain of 12 subjects, and three months later, they generally reported a significant improvement in the physical condition on one side of the brain controlled by the half of the implanted gene, reducing symptoms such as tremors and crampsAccording to the severity of Parkinson's disease, they improved by an average of 25 to 30 percent, and some patients recovered 65 percentOne year after the end of the trial, the efficacy of gene therapy was evaluated and no side effects were seenThe researchers say that while this is a preliminary result, it is a milestone, not only for the treatment of Parkinson's disease, but also for other gene therapies neurotic diseases U.S researchers hope to conduct large-scale trials on more volunteers in the future, targeting both sides of the brain